Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter C Taylor

Showing results (111-120 of 246) with videos related to

Pageof 25
Sort By:
Arthritis Research & Therapy|April 20, 2019
Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trialPeter C Taylor, Didier Saurigny, Jiri Vencovsky, et al.
Plos One|June 24, 2016
Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical TrialsEmilia Quattrocchi, Mikkel Østergaard, Peter C Taylor, et al.
Clinical and Experimental Rheumatology|October 18, 2016
Decrease in articular hypoxia and synovial blood flow at early time points following infliximab and etanercept treatment in rheumatoid arthritisBenjamin A Fisher, Philippe Donatien, Andrew Filer, et al.
Rheumatology (Oxford, England)|September 27, 2024
Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexateMaya H Buch, David Walker, Christopher J Edwards, et al.
Annals of the Rheumatic Diseases|May 30, 2024
Predictors for severe persisting pain in rheumatoid arthritis are associated with pain origin and appraisal of painChristoph Baerwald, Edgar Stemmler, Sixten Gnüchtel, et al.
Rheumatology and Therapy|April 8, 2025
A Comparison of the Immunogenicity of Intravenous BAT1806, a Tocilizumab Biosimilar, and Its Reference ProductHans C Ebbers, Peter C Taylor, Xiaomei Leng, et al.
Rheumatology (Oxford, England)|September 19, 2023
Patterns and determinants of response to novel therapies in juvenile and adult-onset polyarthritisClément Triaille, Pierre Quartier, Lien De Somer, et al.
Arthritis Research & Therapy|November 10, 2005
Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritisAndrew Kinloch, Verena Tatzer, Robin Wait, et al.
Rheumatology Advances in Practice|August 11, 2021
Real-life drug persistence in patients with rheumatic diseases treated with CT-P13: a prospective observational cohort study (PERSIST)Peter C Taylor, Robin Christensen, Shahrzad Moosavi, et al.
Pathology|July 9, 2024
A novel molecular assay conducted on the BD Max system to facilitate reflex testing for vanA and vanB in clinical isolates of enterococciChristopher J McIver, Ryanbi Pratama, Gismin Jose, et al.
Pageof 25

Showing results (111-120 of 246) with videos related to

Sort By:
Pageof 25
Arthritis Research & Therapy|April 20, 2019
Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trialPeter C Taylor, Didier Saurigny, Jiri Vencovsky, et al.
Plos One|June 24, 2016
Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical TrialsEmilia Quattrocchi, Mikkel Østergaard, Peter C Taylor, et al.
Clinical and Experimental Rheumatology|October 18, 2016
Decrease in articular hypoxia and synovial blood flow at early time points following infliximab and etanercept treatment in rheumatoid arthritisBenjamin A Fisher, Philippe Donatien, Andrew Filer, et al.
Rheumatology (Oxford, England)|September 27, 2024
Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexateMaya H Buch, David Walker, Christopher J Edwards, et al.
Annals of the Rheumatic Diseases|May 30, 2024
Predictors for severe persisting pain in rheumatoid arthritis are associated with pain origin and appraisal of painChristoph Baerwald, Edgar Stemmler, Sixten Gnüchtel, et al.
Rheumatology and Therapy|April 8, 2025
A Comparison of the Immunogenicity of Intravenous BAT1806, a Tocilizumab Biosimilar, and Its Reference ProductHans C Ebbers, Peter C Taylor, Xiaomei Leng, et al.
Rheumatology (Oxford, England)|September 19, 2023
Patterns and determinants of response to novel therapies in juvenile and adult-onset polyarthritisClément Triaille, Pierre Quartier, Lien De Somer, et al.
Arthritis Research & Therapy|November 10, 2005
Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritisAndrew Kinloch, Verena Tatzer, Robin Wait, et al.
Rheumatology Advances in Practice|August 11, 2021
Real-life drug persistence in patients with rheumatic diseases treated with CT-P13: a prospective observational cohort study (PERSIST)Peter C Taylor, Robin Christensen, Shahrzad Moosavi, et al.
Pathology|July 9, 2024
A novel molecular assay conducted on the BD Max system to facilitate reflex testing for vanA and vanB in clinical isolates of enterococciChristopher J McIver, Ryanbi Pratama, Gismin Jose, et al.
Pageof 25